⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10296589 | 0.92 | — | — | |
| SCHEMBL158226 | 0.82 | — | — | |
| SCHEMBL24710892 | 0.80 | — | — | |
| Bromide SCHEMBL28296934 | 0.80 | — | — | |
| SCHEMBL5702346 | 0.74 | — | — | |
| SCHEMBL24858297 | 0.71 | — | — | |
| SCHEMBL12133555 | 0.68 | — | — | |
| SCHEMBL13830353 | 0.67 | OR51E2 (0.39) | — | |
| SCHEMBL24287629 | 0.67 | — | — | |
| SCHEMBL22692966 | 0.67 | HTR1D (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105553-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024079623-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2024-04-18 | — | — | WO | disclosed |
| US-11918984-B2 | Annulation catalysts via direct C—H bond amination | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2024-03-05 | — | — | US | disclosed |
| US-20230046859-A1 | Bicyclic Compounds and their Uses | NOVARTIS PHARMA AG (CH) | 2023-02-16 | — | — | US | disclosed |
| US-20220016613-A1 | NOVEL ANNULATION CATALYSTS VIA DIRECT C-H BOND AMINATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-01-20 | — | — | US | disclosed |
| US-11009750-B2 | Liquid crystal display device and method for producing liquid crystal display device | SHARP KABUSHIKI KAISHA (JP) | 2021-05-18 | — | — | US | disclosed |
| US-10831066-B2 | Liquid crystal display device and alignment film | SHARP KABUSHIKI KAISHA (JP) | 2020-11-10 | — | — | US | disclosed |
| WO-2020061300-A1 | NOVEL ANNULATION CATALYSTS VIA DIRECT C-H BOND AMINATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-03-26 | — | — | WO | disclosed |
| US-20190227387-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND METHOD FOR PRODUCING LIQUID CRYSTAL DISPLAY DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2019-07-25 | — | — | US | disclosed |
| US-9982015-B2 | Cyclin based inhibitors of CDK2 and CDK4 | UNIVERSITY OF SOUTH CAROLINA (US) | 2018-05-29 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-20110118285-A1 | HETEROCYCLES AS PROTEIN KINASE INHIBITORS | AMGEN INC. | 2011-05-19 | — | — | US | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| EP-2053041-A2 | 1,3,5-Trisubstituted 2(1H)-pyridones as AMPA receptor inhibitors useful for the treatment of eg Parkinson's disease | Eisai R&D Management Co., Ltd. (JP) | 2009-04-29 | — | — | EP | disclosed |
| EP-1300396-B1 | 1,2-DIHYDROPYRIDINE COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2009-01-14 | — | — | EP | disclosed |
| EP-1465626-B1 | PHARMACEUTICAL COMPOSITIONS (KIT) COMPRISING DIHYDROPYRIDINONE COMPOUNDS AND AN IMMUNOREGULATORY (OR AN ANTIINFLAMMATORY) AGENT AND THEIR USES | EISAI R&D MAN CO LTD (JP) | 2008-09-03 | — | — | EP | disclosed |